INTRON TECH (01760) reported total revenue of approximately RMB5.57 billion for the first three quarters, up about 21.4% year on year.
INTRON TECH (01760) announced a business update for the third quarter ended September 30, 2026. For the nine months ended September 30, 2026, the Group's total revenue was approximately RMB5.57 billion (unaudited), representing a year-on-year increase of approximately 21.4% compared with the same period in 2025.
INTRON TECH (01760) announced a business update for the third quarter ended September 30, 2026. For the nine months ended September 30, 2026, the Group's total revenue was approximately RMB5.57 billion (unaudited), representing a year-on-year increase of approximately 21.4% compared with the same period in 2025.
For the nine months ended September 30, 2026, the Group's semiconductor solutions business revenue was approximately RMB3.521 billion, flat compared with the same period in 2025.
For the third quarter ended September 30, 2026, the Group's semiconductor solutions business revenue was approximately RMB1.398 billion, representing a year-on-year increase of approximately 16.0% compared with the same period in 2025; among this, demand for cloud server business was strong, with revenue of approximately RMB159 million, representing a year-on-year increase of approximately 37.2% compared with the same period in 2025.
For the nine months ended September 30, 2026, the Group's automotive electronics business revenue was approximately RMB2.049 billion, representing a year-on-year increase of approximately 93.5% compared with the same period in 2025.
For the third quarter ended September 30, 2026, the Group's automotive electronics business revenue was approximately RMB772 million, representing a year-on-year increase of approximately 84.7% compared with the same period in 2025; new product power bricks drove the new energy powertrain business to continue growing rapidly, with revenue of approximately RMB574 million, representing a year-on-year increase of approximately 183.5% compared with the same period in 2025.
Related Articles

HEARTCARE-B (06609): Proposed Re-election and Appointment of Directors of the Third Board of Directors

HUTCHMED (00013) Announces SANOVO Phase III Study Data of ORPATHYS Combined with TAGRISSO for First-Line Treatment of EGFR-Mutated Lung Cancer at the 2026 European Society for Medical Oncology (ESMO) Congress

SSY GROUP (02005) reported profit attributable to shareholders of approximately HK$460 million for the first three quarters, up 15.5% year-on-year.
HEARTCARE-B (06609): Proposed Re-election and Appointment of Directors of the Third Board of Directors

HUTCHMED (00013) Announces SANOVO Phase III Study Data of ORPATHYS Combined with TAGRISSO for First-Line Treatment of EGFR-Mutated Lung Cancer at the 2026 European Society for Medical Oncology (ESMO) Congress

SSY GROUP (02005) reported profit attributable to shareholders of approximately HK$460 million for the first three quarters, up 15.5% year-on-year.






